The digital-first Beauty and Personal Care (BPC) company Veerhealth Care Ltd, which sells its Ayuveer range across platforms like Myntra, Amazon, and Nykaa alongside its core manufacturing business, has just picked up a fresh contract manufacturing order from a leading Indian FMCG player. The deal, disclosed to the BSE, comes with a tight execution timeline and adds to what’s already been a strong stretch of quarterly numbers for the company. Details on pricing and volumes remain under wraps, but the filing hints at where Veerhealth’s growth is headed next.
Shares of Veerhealth Care Ltd are trading at Rs. 49.90, up 1.16 percent on Thursday. The stock touched the intraday high of Rs. 50.45 after opening at Rs. 50 before slipping to a low of Rs. 49. The company commands a market capitalization of Rs. 99.79 crore.
Domestic Face-Care Deal
Veerhealth Care Ltd told the BSE on September 2 that it has picked up an order worth Rs. 4.36 Crore from an Indian FMCG company for face care products. The Mumbai-headquartered manufacturer, which runs the Ayuveer personal care brand out of its Vapi facility, has 45 days to deliver. The client hasn’t been named; the company cited confidentiality terms in the filing but it confirmed the deal is domestic and doesn’t involve any related party or promoter interest.
Growth Story Accelerates
The recently secured Rs 4.37 crore order marks a major financial milestone for Veerhealth Care Limited, representing over 13% of the company’s total revenue of Rs 32.48 crore reported for the entire 2026 fiscal year. Veerhealth’s full-year revenue for FY26 came in at Rs. 32.48 crore, so a Rs. 4.37 crore order isn’t a rounding error; it’s north of 13% of what the company did in the entire preceding year, landing on top of whatever else is already booked. The 45-day timeline is tight, which usually means the client wants stock moving fast, and the fact that Veerhealth agreed to it suggests the plant has room to accommodate the run without disrupting existing lines.
Beyond the immediate financial value of the contract, this latest order highlights a broader, accelerating growth pattern for the company. Veerhealth has spent the last couple of years pushing harder into contract manufacturing and private label work, and picking up business from a known FMCG name gives it something to point to when courting the next client. The order also landed at a point when the company’s numbers were already trending up. Q4FY26 revenue came in at Rs. 16.76 crore versus Rs. 5.62 crore in the same quarter last year, and EBITDA more than tripled to Rs. 0.96 crore. Assuming execution goes to plan, this should show up in the current quarter’s revenue and adds another data point to the growth story that began building after the USFDA clearance came through last year.
Financial Performance
Looking at the quarterly results of Veerhealth Care Limited, the company’s standalone revenue from operations increased by 456 percent YOY, from Rs. 4.48 crore in Q1 FY26 to Rs. 24.92 crore in Q1 FY27, and grew by 48.70 percent QoQ from Rs. 16.76 crore in Q4 FY26.
In Q1 FY27, the company’s consolidated net profit increased by 408 percent YOY, reaching Rs. 1.22 crore compared to Rs. 0.24 crore during the same period last year. As compared to Q4 FY26, the net profit has increased by 448.57 percent, from negative of Rs. 0.35 crore.
The basic earnings per share increased by 408.33 percent and stood at Rs. 0.61 as against Rs. 0.12 recorded in the same quarter in the previous year, FY2026
Industry Outlook
When viewed from a broader perspective, this contract aligns closely with a well-established, structural trend currently shaping the Indian fast-moving consumer goods (FMCG) manufacturing landscape. Rising incomes and a growing appetite for clean-label, herbal, and vegan formulations have pushed larger consumer goods companies to lean more on contract manufacturers instead of building out their own capacity; it’s cheaper and faster, provided the vendor can meet quality and compliance standards.
Veerhealth’s USFDA-approved plant puts it in a small pool of Indian small-caps that can credibly serve both domestic private-label demand and export markets. With per-capita oral and skin care consumption in India still well below global norms, there’s a reasonable runway ahead for manufacturers that have already cleared the regulatory bar though scaling output without cutting corners on quality remains the real test.
Company Overview
Veerhealth Care Ltd, listed on the BSE, manufactures pharma and personal care products from its 90,000 sq. ft. USFDA-approved facility in Vapi, Gujarat. Through its Ayuveer brand, the company makes vegetarian, cruelty-free toothpaste, skincare, haircare, and OTC drug products, serving both domestic and export markets including the US, East Africa, and the Middle East.